Eikon Therapeutics (EIKN) CEO adds 284,857 shares after preferred conversion

Rhea-AI Filing Summary

Eikon Therapeutics, Inc. insider Roger M. Perlmutter, the company’s Chief Executive Officer and Director, indirectly acquired 284,857 shares of common stock on February 6, 2026 through derivative conversions tied to the company’s initial public offering.

Series A-1 Preferred Stock representing 1,268,891 shares and Series D Preferred Stock representing 855,512 shares each converted into common stock immediately prior to the IPO closing on a 1-for-7.4578 basis. The resulting common shares are held indirectly for Perlmutter’s benefit through Perlmutter Consulting, Inc., in which he had the sole pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PERLMUTTER ROGER M

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		C		284,857	A	(1)(2)	284,857	I	See Footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-1 Preferred Stock	(1)	02/06/2026		C			1,268,891	(1)	(1)	Common Stock	170,143	(1)	0	I	See Footnote(3)
Series D Preferred Stock	(2)	02/06/2026		C			855,512	(2)	(2)	Common Stock	114,714	(2)	0	I	See Footnote(3)

Explanation of Responses:

1. The Series A-1 Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering ("IPO") on a 1-for-7.4578 basis and had no expiration date.

2. The Series D Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's IPO on a 1-for-7.4578 basis and had no expiration date.

3. The securities are held indirectly by the Reporting Person through Perlmutter Consulting, Inc. for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.

Remarks:

Chief Executive Officer and Director

	/s/ Benjamin Thorner, Attorney-in-Fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did EIKN disclose for Roger M. Perlmutter?

Eikon Therapeutics reported that Chief Executive Officer and Director Roger M. Perlmutter indirectly acquired 284,857 shares of common stock on February 6, 2026 through conversions of preferred stock in connection with the company’s initial public offering.

How many Eikon Therapeutics (EIKN) common shares were acquired in this Form 4?

The Form 4 shows an indirect acquisition of 284,857 shares of Eikon Therapeutics common stock. These shares resulted from the conversion of Series A-1 Preferred Stock and Series D Preferred Stock immediately prior to the closing of the company’s initial public offering.

How were the EIKN preferred shares converted into common stock?

The Series A-1 Preferred Stock and Series D Preferred Stock each converted into common stock immediately prior to the closing of Eikon Therapeutics’ initial public offering on a 1-for-7.4578 basis, as disclosed in the explanation of responses section.

What amounts of preferred stock were involved in the EIKN conversion?

The filing identifies 1,268,891 shares of Series A-1 Preferred Stock and 855,512 shares of Series D Preferred Stock. Both series converted into Eikon Therapeutics common stock immediately prior to the IPO closing, producing the 284,857 indirectly held common shares.

How are Roger M. Perlmutter’s EIKN shares held after the transaction?

The securities are held indirectly for Roger M. Perlmutter’s benefit through Perlmutter Consulting, Inc. The filing notes that the reporting person had the sole pecuniary interest in these securities, even though ownership is reported as indirect.

What transaction code is used in the EIKN Form 4 and what does it mean?

The Form 4 uses transaction code “C,” described as a conversion of derivative security. This indicates that the preferred stock holdings were converted into common stock rather than being bought or sold in an open-market transaction.